This month we are launching our newest publication, Life Science Compliance Update. This publication promises to deliver in-depth analysis of important compliance issues for both pharmaceutical and device companies and those who serve that industry. Each issue covers important news and analysis, with input from top compliance officers and healthcare attorneys across the industry. We encourage you to download the sample issue and consider subscribing.
*** Policy and Medicine readers are entitled to a 15% discount on subscriptions. The discount code is: CHARTER15 ***
Available now, the April 2015 premiere issue of Life Science Compliance Update covers the latest enforcement trends coming out of the Department of Justice, a comprehensive update on HHS-OIG activity, and a thorough breakdown of important state transparency laws and new state bills that could have a big impact on life science companies.
The featured article in April’s issue provides the most comprehensive review and analysis of states’ “Right to Try” acts available. Comparing the States’ “Right To Try” Acts: Effective Legislation or False Hope? was written by David Vulcano, industry regulatory expert and the Responsible Executive for Clinical Research at the Hospital Corporation of America. Click on the image below for more information.